医学
荟萃分析
肿瘤科
转移性乳腺癌
乳腺癌
内科学
癌症
作者
Prajakta P. Masurkar,Prachi Prajapati,Joanne Canedo,Swarnali Goswami,Sally Earl,Kaustuv Bhattacharya
标识
DOI:10.1080/03007995.2024.2402074
摘要
Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have emerged as a significant advancement in the treatment of HR+/HER2- metastatic breast cancer (MBC). Despite the clinical efficacy of CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer, there remains a significant gap in understanding their cost-effectiveness, particularly regarding the long-term economic impact and the key drivers of costs, when used in combination with endocrine therapy. This study aims to systematically review and conduct a meta-analysis of cost-effectiveness studies evaluating CDK4/6 inhibitors in treatment of HR+/HER2- advanced breast cancer and identify key drivers of costs of CDK4/6 inhibitors in combination with endocrine therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI